Background. Whether community-associated methicillin-resistant Staphylococcus aureus (MRSA) genotypes (e.g., USA300) are a major cause of bloodstream infections (BSIs) and health care-associated infections has been poorly defined.
mitted to the intensive care unit in the United States [2] . In recent reports, MRSA caused 4.6%-19% of health care-associated bloodstream infections (BSIs) [3, 4] , and a meta-analysis suggested a significantly higher mortality for MRSA bacteremia, compared with methicillin-susceptible S. aureus bacteremia [5] .
MRSA has traditionally been a nosocomial pathogen. However, over the past few years, MRSA has emerged as an important cause of community-associated infections in both pediatric and adult populations [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] . Community-associated MRSA (CA-MRSA) infections have occurred in the absence of health care-associated risk factors traditionally associated with MRSA infection [6, 8, 25] and have predominantly involved skin and soft tissue [1, 16] . CA-MRSA isolates have been reported to possess a novel staphylococcal chromosomal cassette mec element (SCCmecIV), which is smaller than the SCCmec found in the isolates usually responsible for health care-associated MRSA (HA-MRSA) infections [26] ; and unlike HA-MRSA isolates, CA-MRSA isolates frequently contain genes encoding for Panton-Valentine leukocidine (PVL), a leukocyte-killing exotoxin linked to development of furuncles, cutaneous abscesses, and severe necrotic infections [27] .
Among MRSA isolates recovered from patients in the United States, 8 distinct clusters were originally identified by PFGE and designated USA100-USA800 [28] . Of these, PFGE types USA300 and USA400 were from CA-MRSA infections, while the others were from HA-MRSA infections. A recent study at our institution demonstrated that 72% of all S. aureus skin and soft tissue infections in patients with community onset of infection were caused by MRSA, and that 87% of these MRSA isolates represented CA-MRSA strains (99% of which were PFGE type USA300) [19] . Despite the reported increase in prevalence of CA-MRSA infections, it has not been known to what extent the CA-MRSA strains USA300 and USA400 cause nosocomial infections, especially BSIs. The purpose of our study was to assess whether USA300 strains were a cause of MRSA bacteremia, to assess whether they were a common cause of nosocomial and health care-associated infections, and to determine risk factors associated with BSI due to the USA300 genotype.
PATIENTS, MATERIALS, AND METHODS

Case Definitions and Case Ascertainment
The study took place at Grady Memorial Hospital, a 1000-bed, urban, public hospital in Atlanta, Georgia. The institutional review board at Emory University and the Grady Memorial Hospital Research Oversight Committee approved the study. Prospective laboratory surveillance for blood cultures positive for MRSA was performed during 7.5 months in 2004. S. aureus identification and antimicrobial resistance testing for all isolates were performed in the Grady Memorial Hospital microbiology laboratory according to Clinical and Laboratory Standards Institute standards [29] . A case of MRSA BSI was defined by the first MRSA-positive blood culture (index culture). A second positive blood culture for the same patient defined a new case only if the blood sample for that second index culture was recovered during a subsequent hospitalization 128 days after the first index culture. Medical, laboratory, and pharmacy records were abstracted to collect patient demographic information; past medical history was recorded, including information on substance abuse, prior MRSA infections, HIV serologic status, past or present health care-associated risk factors, time between admission and collection of the sample for the index culture, hospital location where the sample for the index culture was obtained, other bacteriological studies performed during hospitalization, length of stay, and death due to any cause during the hospital stay. "Health care-associated" was defined using previously published definitions [6, 8, 25] , which include nosocomial infection (defined below, in this paragraph) or the presence of any of the following health careassociated risk factors within the year prior to the index culture: (1) receipt of systemic antimicrobial treatment, (2) residence in a long-term care facility, (3) prior admission to an acute care facility, regardless of the duration of hospitalization (excluding clinic visits), (4) use of central intravenous catheters or long-term venous access devices, (5) use of urinary catheters, (6) use of other long-term percutaneous devices (i.e., thoracostomy tubes, nephrostomy tubes, biliary drains, percutaneous endoscopic gastrostomy tubes, traction pins, and external fixtures), (7) prior surgical procedures, and/or (8) need for any form of dialysis. Nosocomial (i.e., hospital-onset) infection was defined by an MRSA-positive culture of a blood sample obtained 148 h after admission. Community-onset infection was defined by an MRSA-positive culture of a blood sample obtained from an outpatient or from an inpatient within 48 h of admission. Health care-associated infections included both community-onset and nosocomial infections. CA-MRSA infection was defined by a community-onset infection in the absence of the health care-associated risk factors described above.
Antimicrobial Susceptibility Testing
In vitro antimicrobial susceptibility testing was done using the Vitek legacy system (bioMérieux) according to manufacturer's instructions and with the Kirby-Bauer disk diffusion method, if needed, in accordance with Clinical and Laboratory Standards Institute standards [29] . Tests to determine inducible clindamycin resistance (the D-zone test) were not performed. Reports of intermediate antimicrobial susceptibility (defined as an MIC of gentamicin of 12 mg/mL but !16 mg/mL, an MIC of erythromycin of 10.5 mg/mL but !8 mg/mL, and an MIC of levofloxacin of 11 mg/mL but !8 mg/mL) and resistant S. aureus were grouped as "non-susceptible."
Molecular Typing Studies
Restriction-enzyme digestion, PFGE, and cluster analysis. After restriction-enzyme digestion was performed with SmaI (Roche Molecular Biochemicals), PFGE of MRSA isolates was performed. Gel photographs were digitized and saved as TIFF files for analysis with BioNumerics Software (Applied Maths). Cluster analysis was performed using unweighted pair-group methodology based on Dice coefficients. PFGE type clusters were defined using a coefficient of similarity of 80%. MRSA isolates were assigned to PFGE type clusters as described elsewhere [28] . SCCmec element type assignment and PVL genotyping. SCCmec genotyping of MRSA isolates was performed using a multiplex PCR method as described elsewhere [30] . The presence of lukS-PV and lukF-PV genes coding for PVL in MRSA isolates was determined by PCR as described elsewhere [27] .
Statistical analysis. Univariate and multivariate analyses were performed using SAS software, version 8.2 (SAS Institute). A case-control study was carried out to assess risk factors associated with recovery of MRSA USA300 from patients with MRSA BSIs. Patients in the case group had MRSA BSI due to the USA300 genotype; patients in the control group had BSI due to HA-MRSA genotypes (i.e., non-USA300 or non-USA400 genotypes), including PFGE types USA100, USA500, and USA800. In addition, risk factors for crude in-hospital mortality rates were assessed in a separate analysis using a case-control study design. In this analysis, patients in the case group were those with MRSA BSI who died of any cause during the hospital stay; patients in the control group were those with MRSA BSI who survived to the time of hospital discharge. Potential risk factors were first assessed by univariate analysis. Proportions were compared using Pearson x 2 test and Fisher's exact test, as appropriate. For dichotomous variables, the Mantel-Haenszel ORs and corresponding 95% CIs were calculated. Variables significantly associated with the outcome of interest (PFGE type USA300 and increased risk of death) in univariate analysis, potential effect modifiers and confounders were entered in the respective multivariate models. Multivariate analysis was performed using an unconditional logistic regression model. Possible two-way interactions among main effect variables and confounding were examined. The final model was derived by incorporating a hierarchical backward elimination approach. Goodness of fit for the final logistic regression model was assessed. A P value of р.05 was defined as statistically significant.
RESULTS
A total of 132 cases of MRSA BSI were observed in 128 patients during the 7.5-month study period, for an incidence of 6.79 cases per 1000 patient admissions. A total of 116 MRSA isolates were available for further study. There was no statistically significant difference in demographic characteristics between the 16 cases without isolates available and the 116 cases with isolates available for genotyping (data not shown).
Patient and infection characteristics. Patient demographic information and other characteristics of the 116 cases of MRSA BSI are shown in table 1 and table 2. The mean age of patients was 47 years, 62% were male, 38% were female, and 82% were African American. Seventy-two percent of patients were admitted from a private residence. There were 7 patients (6%) with endocarditis evidenced by echocardiogram findings; 22% were HIV seropositive, with a median CD4 cell count of 28 cells/mL. There were 107 cases (92%) with at least one health care-associated risk factor as defined in the Methods section, and only 9 (8%) did not have any and were classified as community-associated infection (figure 1). Sixty-seven (58%) MRSA BSIs were community-onset (of which 58 occurred in patients with у1 health care-associated risk factor and 9 were community-associated) and 49 (42%) MRSA BSIs were nosocomial, defined by index cultures obtained 148 h after admission of the patient (figure 1). The mean length of hospital stay was 30.2 days (median, 18 days; range, 1-241 days). The crude in-hospital mortality rate was 22%.
Genotyping of MRSA isolates. Molecular typing results of MRSA isolates by PFGE and PCR are shown in tables 3 and 4, and PFGE cluster analysis is shown in figure 2 . A total of 39 (34%) of 116 MRSA isolates were PFGE type USA300; 34 (29%) were USA100; 42 (36%) were USA500; and 1 (1%) was USA800. All isolates could be assigned to 1 of these 4 PFGE types, and there were no USA200, USA400, USA600, or USA700 isolates recovered from patients with MRSA bacteremia. Thirty (28%) of 107 isolates from health care-associated cases (i.e., those from patients with у1 health care-associated risk factor) and 10 (20%) of the 49 nosocomial MRSA isolates were the USA300 genotype (table 3) . All isolates of the USA300, USA500, and USA800 genotypes carried the SCCmecIV element, and all isolates with PFGE type USA100 carried the SCCmecII element (table 4). All USA300 isolates were positive for the PVL genes lukS-PV and lukF-PV. None of the USA100, USA500, or USA800 isolates contained PVL genes (table 4). HIV infection was significantly more common among the cases with USA300 and USA500 genotypes than the cases with PFGE type USA100 (26 ). The mean and median time from ad-P ! .001 mission to index culture for cases with isolates that had the SCCmecIV element (for USA300, a mean of 4.1 days and a median of 0 days, and for USA500, a mean of 5.6 days and a median of 0 days) were significantly shorter than the time for cases infected with USA100 isolates carrying SCCmecII (mean, 18.0 days; median 8.0 days) (OR, 1.06 per day; 95% CI, 1.01-1.11;
). The crude in-hospital mortality rate was lowest P p .01 among patients infected with MRSA USA300, compared with patients infected with the USA100 or USA500 genotypes ( Antimicrobial susceptibility. All MRSA isolates were vancomycin-susceptible. MRSA blood isolates with the health careassociated genotypes USA100, USA500, or USA800 were significantly more likely to be nonsusceptible to antibacterials other than b-lactams and erythromycin (i.e., clindamycin, levofloxacin, rifampin, gentamicin, and trimethoprim-sulfameth- ). P ! .001 Univariate analysis. Demographic and clinical characteristics associated in univariate analysis with the recovery of the USA300 genotype, compared with those associated with the recovery of the traditional health care-associated genotypes USA100, USA500, and USA800 are shown in tables 1 and 2. These include younger age, admission to the hospital from a private residence, injection drug use, the absence of any health care-associated risk factors, BSI secondary to a skin and soft tissue infection, and lower mortality. Conversely, residence in a long-term care facility, previous hospitalization, systemic antimicrobial use, nosocomial BSI, and current hospitalization in an intensive care unit were factors less likely to be associated with the recovery of the USA300 genotype (tables 1 and 2) .
Multivariate analysis. In a multivariate analysis, independent risk factors for recovery of MRSA USA300 from blood culture included concurrent skin and soft tissue infection (OR, 3.67; 95% CI, 1.10-12.28) and injection drug use (OR, 4.26; 95% CI, 1.08-16.84). Patients who had lived in a long-term care facility (OR, 0.09 for USA300; 95% CI, 0.01-0.82) and persons who had a history of antimicrobial use (OR, 0.10 for USA300; 95% CI, 0.02-0.49), both within the prior year, were significantly less likely to have had PFGE type USA300 recovered (table 5) . Multivariate analysis for independent risk factors associated with in-hospital mortality is shown in table 6.
DISCUSSION
Over the past few years, MRSA has emerged as a cause of community-associated infections among patients without the traditional risk factors associated with health care contact [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] . CA-MRSA genotypes appear to have evolved in the community as opposed to having spread from the health care en- [28] ; unweighted pair-group methodology based on Dice coefficients was used. PFGE type clusters are shown from top to bottom: USA100, 34 isolates; USA800, 1 isolate; USA300, 39 isolates; USA500, 42 isolates. All isolates recovered from MRSA BSIs could be assigned to 1 of these 4 PFGE types. No USA700, USA400, USA600, pr USA200 isolates were detected. (the single case with a USA800 genotype was excluded for these analyses). .08 NOTE. The model controls for collecting blood in the intensive care unit, indwelling device, and nonsurgical procedures within 12 months. No significant interaction was detected during multivariate analysis. The main risk factor was concurrent skin and soft-tissue infection; important confounders were collection of blood in the intensive care unit, having an indwelling device, undergoing a nonsurgical procedure, and antimicrobial use, all within 12 months prior to having an index culture performed.
a Indwelling devices include central intravenous catheters, long-term venous access devices, urinary catheters, and other long-term percutaneous devices. b Nonsurgical procedures include cardiac catheterization, arterial angiogram, upper endoscopy, colonoscopy, bronchoscopy, tracheostomy, bone marrow biopsy, and renal biopsy.
vironment. Evidence to support this comes in part from the fact that CA-MRSA PFGE types USA300 and USA400 contain the novel SCCmecIV element, which is considerably smaller than SCCmec elements I, II, and III, which are found in traditional HA-MRSA strains [26] . The smaller SCCmecIV element may enable more-efficient horizontal transfer and a potentially faster growth rate. These factors may be related to the emergence and explosive spread infection due to CA-MRSA strains in the United States and other countries [10, 31, 32] . CA-MRSA has been described primarily in patients with skin and soft tissue infections [1, 16] . At our institution, we have noted that 72% of community-onset S. aureus skin and soft tissue infections were caused by MRSA, 87% of which were caused by CA-MRSA strains [19] -almost exclusively the USA300 genotype. The frequency of other types of infections due to CA-MRSA genotypes has been unclear. The very first reports of CA-MRSA infection described patients with severe pneumonia and BSI, with some fatal outcomes [6, 7] . More recently, cases of necrotizing pneumonia and necrotizing fasciitis have been linked to PVL-producing MRSA strains [21, 24] . To date, there have been limited data on the potential of CA-MRSA genotypes to cause nosocomial infections. Saiman et al. [33] described a total of 8 postpartum women who developed skin and soft tissue infections due to MRSA USA400 between 4 and 73 days after delivery; all but 1 developed the infection after being discharged from the hospital. Kourbatova et al. [34] recently reported a cluster of MRSA USA300-associated prosthetic joint infections at our institution.
Our current investigation demonstrates that infection due to CA-MRSA USA300 has emerged as a major cause of health care-associated and nosocomial MRSA BSI. We have shown with molecular typing studies that the MRSA USA300 genotype accounted for more than one-third of MRSA BSIs, including 28% of 107 HA-MRSA BSIs, and 20% of 49 nosocomial MRSA BSIs. Even though 58% of the cases were community-onset disease, as evidenced by the results of index culture samples obtained within 48 h after admission, only 9 cases of 116 did not have any health care-associated risk factors. Thus, the PVLpositive USA300 genotype is no longer solely a cause of community-associated infections, but it has also been introduced into our health care facility and causes a significant proportion of health care-associated and nosocomial MRSA infections at our institution. In multivariate analysis, independent risk factors for recovery of the USA300 genotype from patients with MRSA BSI included concurrent skin and soft tissue infections (OR, 3.67) and injection drug use (OR, 4.26). Both risk factors have been linked to CA-MRSA infections in previous reports [16, [35] [36] [37] . The association of infection due to USA300 with these specific comorbidities may be related to the presence of PVL as a virulence factor in USA300 isolates and suggests that specific types of health care exposure may play a role in the transmission of USA300 strains. In addition, for some patients with health careassociated infection but not nosocomial infection, acquisition of the MRSA USA300 genotype may have occurred in the community. Patients who resided in a long term care facility (OR for USA300, 0.09) and those who had had systemic antimicrobial treatment (OR, 0.10) within the prior year were less likely to have PFGE type USA300 recovered and more likely to have one of the "traditional" health care-associated genotypes (USA100, USA500, or USA800) recovered.
These findings demonstrate that our current infection control practices, aimed at the prevention of MRSA infection spread from patients with symptomatic disease and mainly limited to the hospital setting, may not be sufficient to contain this highly adaptive organism. A recent report by our group demonstrated that 17% of patients admitted to our institution were colonized with MRSA at the time of hospital admission; one-third of them (2.2% of all admissions) were colonized with the USA300 genotype [38] . Such patients may have served as a source of introduction of MRSA USA300 into health care settings with subsequent cross-transmission. Alternatively, some patients may have been colonized with MRSA USA300 before they arrived, and they subsequently developed nosocomial infection after hospitalization. Whether the routine implementation of the "search and destroy" strategy (performing active surveillance cultures for MRSA and isolating those who are infected or colonized), as suggested by the Society for Healthcare Epidemiology of America [39] , will be able to control the prevalence of MRSA infection in areas of endemicity is still being debated [40] , and routine surveillance is not part of the current guidelines for isolation precautions in hospitals, which were recommended by the Centers for Disease Control and Prevention [41] . An ongoing, randomized, controlled trial on the effect of performing routine surveillance cultures for MRSA and vancomycin-resistant Enterococcus species by the Bacteriology and Mycology Study Group of the National Institute of Allergy and Infectious Diseases/National Institutes of Health may provide the data needed to assess whether these measures should be included in future guidelines.
MRSA BSIs were common at our institution, with a rate of 6.79 infections per 1000 hospital admissions, higher than those reported from other institutions, which ranged from 10 cases in 5 years at a university hospital in Germany [42] to 2.10 cases per 1000 intensive care unit admissions at a 1060-bed university hospital in Belgium [43] , and, more recently, 0.44 cases per 1000 hospital admissions in an 850-bed community hospital in Italy [44] and 1.48 cases per 1000 hospital admissions in 17 Australian hospitals [32] . This may, in part, be related to the high prevalence of both community-and hospital-onset MRSA infection and predisposing factors, such as low socioeconomic status and injection drug use, in the community served by our institution [19, 22] .
The crude in-hospital mortality rate of 22% we found is on the lower side of the range reported by previous studies on S. aureus BSI (the median mortality rate for MRSA BSI reported in a recent meta-analysis of 31 cohort studies was 32%, with a range of 0%-83.3% [5] ). Reasons for this may be the relatively young average age of patients and the frequent inclusion of vancomycin in the empirical antimicrobial regimen for grampositive bacteria recovered from blood cultures at our institution. Multivariate analysis for independent risk factors associated with mortality identified treatment in an intensive care unit (OR, 16.61), an age of 155 years (OR, 8.09), as well as female sex (OR, 3.88). Comorbidity, age, and female sex all have been associated with increased risk of death in a previous study of S. aureus bacteremia, which also demonstrated a large proportion of community-associated disease [45] .
In conclusion, BSIs due to MRSA USA300 isolates containing PVL genes have been introduced into the hospital environment from the community. Infection with this genotype now accounts for 20% of all nosocomial and 28% of all health careassociated MRSA BSIs at our institution. The emergence of MRSA USA300 in the community and its status as a major cause of health care-associated bacteremias present new and additional challenges to infection control programs.
